Material Event (Form 8-K)

Item 8.01. Other Events

On August 7, Raphael Pharmaceutical Inc. (the "Company" or "Raphael") completed its product development and is ready to launch its proprietary natural formula under the "RaphaWell" Brand for rheumatoid arthritis ("RA") support in the United States. This follows the successful completion of a proof-of-concept clinical trial (the "Study"), conducted under IRB approval and in full compliance with FDA regulations, including participants with severe RA, as previously disclosed on a Form 8-K on December 30, 2024. The Company intends to engage with a manufacturer in the United States to scale production.

The finalized "RaphaWell" product, will be sold as a standalone clinically tested dietary supplement targeting the growing wellness market. The "RaphaWell" product is 100% natural, plant-based, and was associated with no reported side effects during the Study, addressing a significant unmet need in RA symptom management.

Raphael's "RaphaWell" formula has undergone clinical testing, which we believe sets it apart in both credibility and efficacy from other products in the market. As previously disclosed in the Company's Current Report on Form 8-K, filed on December 30, 2024, the Study results showed an improvement in health-related parameters, as evaluated through questionnaires. For example, pain levels dropped from 75% participants reporting a negative result to 50% in week 8 and morning stiffness showed a notable reduction from 75% participants reporting such symptom at baseline to 41.67% at week 8.

We believe that Raphael's "RaphaWell" formula holds strong commercial potential and first-mover advantage. Detailed study data will be available to consumers via QR code on the product packaging.